IsomAb Announces the Expansion of its Clinical Advisory Board

News provided by

Jul 10, 2024, 08:00 ET

NOTTINGHAM, England, July 10, 2024 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced the expansion of its Clinical Advisory Board (CAB); the key role will be to provide expert clinical knowledge and advice on future clinical trials for the company's lead programme. The CAB consists of renowned international experts in the fields of vascular surgery and management of diabetic patients with vascular complications. Many of the CAB members have collaborated on recent clinical trials in limb ischaemia including the PACE PIII trial¹

Jackie Turnbull, CEO of IsomAb Ltd, said: "The expansion of our Clinical Advisory Board comes at an exciting time for our Company as we continue to generate preclinical data in support of ISM-001, a high affinity, humanised antibody designed to restore blood flow in diabetic vascular disease. As we advance our program, we have access to an extraordinary group of renowned clinical experts, who will provide key insights and recommendations to help guide the clinical trial program."

The Clinical Advisory Board consists of the following members:

Prof. Dr. Maarit Venermo – CAB Chair

Professor Venermo is head of the department of vascular surgery at Helsinki University Hospital. Her research concerns registry studies aiming to evaluate the quality of vascular surgical service as well as international variation in practice. Professor Venermo is currently the Secretary General of the European Society for Vascular Surgery (ESVS) and has been a member, or other role, of eleven national/international committees, councils and boards. She has been named on 276 publications in the field of vascular surgery.

Prof. Dr. med. Sigrid Nikol

Professor Nikol trained in thoracic and cardiovascular surgery early in her career, then became an interventional cardiologist and interventional vascular physician. She is Head of Department of Interventional Angiology, St. Georg Hospital in Hamburg Germany. She worked in the early nineties with the pioneer of angiogenesis therapy, Jeffrey Isner MD in Boston, USA. She has over 30 years of experience in translational angiogenesis research, which includes preclinical work and active roles in numerous clinical angiogenesis trials, as Principal Investigator as well as being a member of numerous Steering Committees or Advisory Boards. She has authored more than 231 publications in the cardiovascular field including current guidelines. She is past-president of the European Society for Vascular Medicine (ESVM), a member of the German Angiology Society, and the International Andreas Gruentzig Society.

Professor Robert Hinchliffe

Professor Hinchliffe is a Clinical Professor of Vascular Surgery at Bristol Medical School, and the Chair for the Research for Patient Benefit Southwest region. He is Honorary Consultant Vascular Surgeon in the Bristol, Bath, Weston Vascular Network and an academic vascular surgeon with an interest in diabetes related complications of the lower limb and peripheral artery disease. His research interest is in clinical trials and the evaluation of innovative technologies in surgery.

Marc P. Bonaca, M.D., MPH

Marc P. Bonaca, MD, MPH is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. He is a member of the Society of Vascular Medicine, American College of Cardiology (ACC) and American Heart Association (AHA). He currently serves on the ACC PVD Leadership Council and is an associate editor for the Vascular Medicine.

Professor John C. Lantis

Professor Lantis II, MD, is currently the site Chief and Professor of Surgery at Mount Sinai West Hospital, and the Icahn School of Medicine; in mid-town Manhattan where he practices as a senior vascular surgeon. He is the past president of the New York Vascular Surgery Society, a founding member of the American Board of Wound Medicine and Surgery, and the Vascular Study Group of New York. He is a world leader in limb salvage and lower extremity wound healing and has been a principal investigator on over 70 clinical trials.

Joseph L. Mills, M.D., FACS

Joseph L. Mills, M.D. is a board-certified vascular surgeon in Houston, Texas specializing in diabetic foot amputation prevention and limb salvage. Dr. Mills has authored nearly 300 peer-reviewed journal articles and book chapters, focused on his clinical and research interests in non-invasive diagnosis, vein graft stenosis, intimal hyperplasia and limb-salvage in patients with diabetes mellitus. He has been the principal investigator for over 40 clinical trials, including a number of current investigations.

Professor Michael Edmonds

Professor Edmonds is a Consultant Physician at King's College Hospital in London with a special responsibility for care of the diabetic foot. He developed a multi-disciplinary diabetic foot clinic in 1981, one of the first in the world. He won the Karel Bakker award at the 6^th International Symposium on the Diabetic Foot in 2011 and more recently in 2013 the DFSG Achievement Award. He has also won the Edward James Olmos award for the advocacy in amputation prevention at the DF Con 2014 and gave the Arnold Bloom lecture at Diabetes UK in 2015.

Professor Stephen Bain

Professor Bain is the Clinical Director of the Diabetes Research Unit at Swansea University and Medical Director for Research & Development for Swansea Bay University Health Board. He is also the Chair of the National Specialist Advisory Group (NSAG) for Diabetes in Wales and has been Chief Investigator for several multi-centre trials investigating novel therapies for diabetes; these include LEADER, SUSTAIN 6, PIONEER 6 and most recently SOUL.

¹ - PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial. January 2024; BJS (British Journal of Surgery) 111(2)

For further information please contact: IsomAb Ltd; E: [email protected]

Notes to Editors

About IsomAb Ltd

IsomAb Ltd, founded in 2022, is a UK-based biopharmaceutical company and is a spin-out from the University of Nottingham; early research was conducted at the University of Bristol and funding has been received from the British Heard Foundation, Wellcome Trust and the Medical Research Council. The Company was founded by Prof. David Bates and Prof. Steve Harper based on ground-breaking research into VEGF-A and its splice isoforms and focusses on the development of isoform specific antibodies for disease modifying treatment of life limiting diseases with peripheral ischaemia. ISM-001 is high affinity, humanised antibody to restore blood flow in diabetic vascular disease. For more information, visit: www.isomab.bio.

Logo - https://mma.prnewswire.com/media/2457243/Isomab_logo.jpg

SOURCE IsomAb